查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600464

氣喘治療市場：依產品、藥物類別、給藥途徑 - 2025-2030 年全球預測

Asthma Therapeutics Market by Product (Inhalers, Nebulizers), Drug Class (Anti-Inflammatory, Bronchodilators, Combination Therapy), Route of administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年氣喘治療市值為247億美元，預計2024年將達272.6億美元，複合年成長率為10.63%，預計到2030年將達到501億美元。

氣喘治療市場包括一系列旨在緩解和控制氣喘症狀的產品和治療方法，氣喘是一種影響全球數百萬人的慢性呼吸道疾病。由於都市化、污染和遺傳易感性等因素，氣喘盛行率不斷上升，凸顯了對有效氣喘治療的需求。這些治療方法包括從立即緩解藥物（如支氣管擴張劑）到長期控制藥物（如吸入性皮質類固醇和生技藥品），並根據氣喘的嚴重程度進行調整。最終用途範圍主要包括患者接受治療或自我管理的醫院、診所和居家醫療機構。

主要市場統計
基準年[2023] 247億美元
預測年份 [2024] 272.6億美元
預測年份 [2030] 501億美元
複合年成長率（%） 10.63%

該市場的關鍵成長要素包括環境過敏原的增加、藥物輸送系統（例如智慧吸入器）的技術進步以及更容易患呼吸道疾病的老年人數量的增加。新的商機在於個人化醫療，其中專注於基因組和表現型分析的研究可以帶來量身定做的治療策略。不斷擴大的生物製藥產業也透過開發新型生技藥品提供了一條利潤豐厚的道路。公司應利用與高科技公司的合作夥伴關係來開發智慧監控系統，並利用遠端醫療的潛力來提高患者的依從性。

然而，治療成本高、長期使用氣喘藥物可能產生的副作用以及用藥依從性不一致等挑戰正在阻礙市場成長。此外，監管限制和新藥認證的管線延誤也增加了市場挑戰。為了確保業務成長，公司應專注於開發負擔得起的學名藥，投資於創新製劑的研發，並加強教育計畫以提高對氣喘管理的認知。

氣喘治療市場是一個充滿活力的市場，需要不斷創新以適應不斷變化的醫療需求。透過解決高成本並關注患者教育，公司可以顯著影響患者的治療效果並充分利用成長機會。在精準醫療的引領下，市場可望取得重大進展。

市場動態：揭示快速發展的氣喘治療市場的關鍵市場洞察

供需的動態交互作用正在改變氣喘治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 氣喘和其他呼吸道疾病的增加
    • 過敏檢測和診斷技術的最新進展
    • 對單株抗體的需求不斷成長
  • 市場限制因素
    • 氣喘治療設備的限制和副作用
  • 市場機會
    • 治療聯合療法的開發
    • 氣喘治療的廣泛研究與發展 (R&D) 工作
  • 市場問題
    • 偏遠和農村地區接受治療方法的情況有限

波特五力：開拓氣喘治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解氣喘治療市場的外在影響

外部宏觀環境因素在塑造氣喘治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解氣喘治療市場的競爭格局

對氣喘治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：氣喘治療市場供應商的績效評估

FPNV定位矩陣是評估氣喘治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 氣喘和其他呼吸道疾病的發生率增加
      • 過敏檢測和診斷技術的最新進展
      • 對單株抗體的需求不斷成長
    • 抑制因素
      • 氣喘治療設備的限制和副作用
    • 機會
      • 治療聯合治療的開發
      • 氣喘治療的廣泛研究和開發工作
    • 任務
      • 偏遠和農村地區的治療供應有限
  • 市場區隔分析
    • 產品：用於氣喘治療的定量吸入器的需求增加
    • 藥物類別：增加發炎藥物在氣喘治療的使用
    • 給藥途徑：擴大吸入性氣喘藥物的使用以實現快速緩解
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境
  • 客戶客製化

第6章氣喘治療市場：依產品

  • 介紹
  • 吸入器
    • 乾粉吸入器
    • 定量吸入器
    • 緩霧吸入器
  • 噴霧器

第7章氣喘治療市場：依藥物類別

  • 介紹
  • 發炎（藥
  • 支氣管擴張劑
  • 聯合治療

第8章氣喘治療市場：依給藥途徑分類

  • 介紹
  • 吸入
  • 口服

第9章美洲氣喘治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太氣喘治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的氣喘治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • GSK 斥資 14 億美元收購 Aiolos Bio，強化呼吸產品組合
    • Teva 和 Biolojic Design 宣布簽署獨家授權合約，開發治療異位性皮膚炎和氣喘的抗體
    • Lupin 推出成人氣喘和慢性阻塞性肺病治療藥物“Lufovec (R) 100/6”

公司名單

  • Genentech, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • Chiesi Farmaceutici SpA
  • Boston Scientific Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Medtronic PLC
  • Softhale NV by invoX Pharma Limited
  • Koninklijke Philips NV
  • Wellinks, Inc.
  • Viatris Inc.
  • Amgen Inc.
  • Sanofi SA
  • Biogen Inc.
  • AstraZeneca PLC
  • Merck & Co, Inc.
  • Parekhplast India Limited
  • GlaxoSmithKline PLC
  • Kare Medical and Analytical Devices Ltd. Co.
  • Sun Pharmaceutical Industries Limited
  • Abbott Laboratories
  • Shenzhen Aeon Technology Co., Ltd.
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd
  • Lupin Limited
  • Trudell Medical Limited
  • Cipla Limited
  • Merxin Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
Product Code: MRR-AB49FC1AB810

The Asthma Therapeutics Market was valued at USD 24.70 billion in 2023, expected to reach USD 27.26 billion in 2024, and is projected to grow at a CAGR of 10.63%, to USD 50.10 billion by 2030.

The asthma therapeutics market encompasses a wide array of products and treatments aimed at alleviating symptoms and managing asthma, a chronic respiratory condition affecting millions globally. The necessity for effective asthma therapeutics is underscored by the rising prevalence of asthma, attributable to factors such as urbanization, pollution, and genetic susceptibility. The application of these therapeutics spans from quick-relief medications, like bronchodilators, to long-term control agents, including inhaled corticosteroids and biologics, tailored to various grades of asthma severity. End-use scope primarily includes hospitals, clinics, and homecare settings, where patients either receive or self-administer treatment.

KEY MARKET STATISTICS
Base Year [2023] USD 24.70 billion
Estimated Year [2024] USD 27.26 billion
Forecast Year [2030] USD 50.10 billion
CAGR (%) 10.63%

Key growth influencers in the market include an increase in environmental allergens, technological advancements in drug delivery systems (like smart inhalers), and an expanding geriatric population who are more prone to respiratory ailments. Emerging opportunities lie in personalized medicine, with research focusing on genomic and phenotypic profiling leading to tailored therapeutic strategies. The expanding biopharmaceutical sector also presents lucrative avenues through the development of novel biologics. Companies should leverage partnerships with tech firms to develop intelligent monitoring systems and improve patient adherence, tapping into the potential of telemedicine.

However, market growth is hindered by challenges such as high treatment costs, potential side effects of long-term asthma medication use, and inconsistent medical adherence. Furthermore, regulatory constraints and a slow pipeline for new drug approvals add to market challenges. To ensure business growth, companies should focus on developing affordable generics, invest in R&D for innovative drug formulations, and enhance educational programs to raise awareness of asthma management.

The asthma therapeutics market is dynamic, requiring continuous innovation to adapt to evolving healthcare needs. By addressing high costs and emphasizing patient education, businesses can significantly impact patient outcomes and capitalise on growth opportunities. With precision medicine leading the way, the market is poised for significant advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Asthma Therapeutics Market

The Asthma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Incidences of Asthma and Other Respiratory Diseases
    • Recent Improvements in Allergy Detection and Diagnostic Technologies
    • Extensive Demand for Monoclonal Antibodies
  • Market Restraints
    • Limitation and Side Effects of Asthma Therapeutic Devices
  • Market Opportunities
    • Development of Combination Therapeutics for The Treatment
    • Extensive Research and Development (R&D) Efforts for Asthma Treatment
  • Market Challenges
    • Limited Therapeutics Reach in Remote & Rural Areas

Porter's Five Forces: A Strategic Tool for Navigating the Asthma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Asthma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Asthma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Asthma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Asthma Therapeutics Market

A detailed market share analysis in the Asthma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Asthma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Asthma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Genentech, Inc., Pfizer Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Boston Scientific Corporation, Sunovion Pharmaceuticals, Inc., Medtronic PLC, Softhale NV by invoX Pharma Limited, Koninklijke Philips N.V., Wellinks, Inc., Viatris Inc., Amgen Inc., Sanofi S.A., Biogen Inc., AstraZeneca PLC, Merck & Co, Inc., Parekhplast India Limited, GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Sun Pharmaceutical Industries Limited, Abbott Laboratories, Shenzhen Aeon Technology Co., Ltd., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Lupin Limited, Trudell Medical Limited, Cipla Limited, Merxin Ltd., Novartis AG, and Regeneron Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Inhalers and Nebulizers. The Inhalers is further studied across Dry Powder Inhalers, Metered-Dose Inhalers, and Soft Mist Inhalers.
  • Based on Drug Class, market is studied across Anti-Inflammatory, Bronchodilators, and Combination Therapy.
  • Based on Route of administration, market is studied across Inhaled and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Incidences of Asthma and Other Respiratory Diseases
      • 5.1.1.2. Recent Improvements in Allergy Detection and Diagnostic Technologies
      • 5.1.1.3. Extensive Demand for Monoclonal Antibodies
    • 5.1.2. Restraints
      • 5.1.2.1. Limitation and Side Effects of Asthma Therapeutic Devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of Combination Therapeutics for The Treatment
      • 5.1.3.2. Extensive Research and Development (R&D) Efforts for Asthma Treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Therapeutics Reach in Remote & Rural Areas
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for metered dose inhalers for the treatment of asthma
    • 5.2.2. Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
    • 5.2.3. Route of administration: Expanding adoption of inhaled asthma medication for fast relief
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Asthma Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Inhalers
    • 6.2.1. Dry Powder Inhalers
    • 6.2.2. Metered-Dose Inhalers
    • 6.2.3. Soft Mist Inhalers
  • 6.3. Nebulizers

7. Asthma Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Inflammatory
  • 7.3. Bronchodilators
  • 7.4. Combination Therapy

8. Asthma Therapeutics Market, by Route of administration

  • 8.1. Introduction
  • 8.2. Inhaled
  • 8.3. Oral

9. Americas Asthma Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Asthma Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Asthma Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
    • 12.3.2. Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
    • 12.3.3. Lupin Launches Luforbec(R) 100/6 for Adult Asthma and COPD Treatment

Companies Mentioned

  • 1. Genentech, Inc.
  • 2. Pfizer Inc.
  • 3. Takeda Pharmaceutical Company
  • 4. Teva Pharmaceutical Industries Ltd.
  • 5. Chiesi Farmaceutici S.p.A.
  • 6. Boston Scientific Corporation
  • 7. Sunovion Pharmaceuticals, Inc.
  • 8. Medtronic PLC
  • 9. Softhale NV by invoX Pharma Limited
  • 10. Koninklijke Philips N.V.
  • 11. Wellinks, Inc.
  • 12. Viatris Inc.
  • 13. Amgen Inc.
  • 14. Sanofi S.A.
  • 15. Biogen Inc.
  • 16. AstraZeneca PLC
  • 17. Merck & Co, Inc.
  • 18. Parekhplast India Limited
  • 19. GlaxoSmithKline PLC
  • 20. Kare Medical and Analytical Devices Ltd. Co.
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Abbott Laboratories
  • 23. Shenzhen Aeon Technology Co., Ltd.
  • 24. Boehringer Ingelheim GmbH
  • 25. F. Hoffmann-La Roche Ltd
  • 26. Lupin Limited
  • 27. Trudell Medical Limited
  • 28. Cipla Limited
  • 29. Merxin Ltd.
  • 30. Novartis AG
  • 31. Regeneron Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. ASTHMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ASTHMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ASTHMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ASTHMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED-DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023